Skip to main content
NVDA-0.14%AAPL+0.07%MSFT+0.25%GOOGL+1.19%AMZN+0.20%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA+0.06%META-0.07%LLY+0.22%BRK-B-1.02%MU-0.26%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%USDJPY+0.72%EURUSD-0.66%AUDJPY+0.62%EURAUD-0.56%GBPUSD-0.51%USDCHF+0.47%GBPAUD-0.42%GBPTRY+0.41%CADJPY+0.40%AUDCHF+0.39%NZDJPY+0.38%EURNZD-0.35%USDCAD+0.33%NZDUSD-0.33%GBPHKD+0.32%EURCAD-0.32%GBPMXN-0.28%USDTRY+0.27%CHFJPY+0.25%AUDNZD+0.23%AUDCAD+0.22%GBPCAD-0.20%EURCHF-0.20%GBPJPY+0.19%GBPNZD-0.18%USDILS+0.16%NZDCHF+0.15%CADCHF+0.15%EURGBP-0.14%AUDUSD-0.10%EURJPY+0.07%CHFSGD+0.05%GBPCHF-0.05%EURSGD+0.05%AUDSGD+0.05%EURCNH+0.05%USDDKK-0.05%NZDMXN+0.04%USDMXN+0.04%USDCOP-0.04%USDCNH-0.04%USDHKD+0.03%AUDNOK+0.03%USDZAR+0.03%NZDSGD+0.02%USDTHB+0.01%NZDCAD-0.01%SGDJPY+0.01%GBPSGD+0.01%USDSGD0.00%EURPLN0.00%CHFNOK0.00%PLNJPY0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURCZK0.00%EURNOK0.00%EURSEK0.00%EURZAR0.00%GBPZAR0.00%AUDDKK0.00%CHFSEK0.00%USDNOK0.00%EURDKK0.00%XNGUSD+0.44%USOIL-0.22%XPTUSD+0.12%HG1-0.05%GAUUSD-0.05%XAUUSD-0.05%GAGUSD-0.04%XAGUSD-0.03%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.95%ETHUSD+23.96%USDTUSD+0.05%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.79%ZECUSDT+6.40%DOGEUSD+20.65%XMRUSDT+1.68%LINKUSD+25.58%BCHUSDT+4.79%XLMUSD+0.36%UNIUSD-1.14%LTCUSD+17.89%SUIUSD+1.32%HBARUSDT-1.82%TONUSD+41.71%TAOUSDT+1.65%AAVEUSD-1.68%DOTUSDT-1.29%ICPUSDT-1.45%ONDOUSDT+0.94%WLDUSDT+0.37%ARBUSDT-1.45%JUPUSDT+0.30%INJUSDT-1.46%ATOMUSDT-0.82%STXUSDT-1.40%TIAUSDT-2.34%FETUSDT+4.01%PYTHUSDT-3.09%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+0.70%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.73%POLUSDT+1.16%AXSUSDT+1.04%EOSUSDT+1.14%FARTCOINUSDT+2.04%DYDXUSDT+2.68%GALAUSDT+1.56%ORDIUSDT+2.76%RONINUSDT+1.89%NOTUSDT+1.92%NVDA-0.14%AAPL+0.07%MSFT+0.25%GOOGL+1.19%AMZN+0.20%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA+0.06%META-0.07%LLY+0.22%BRK-B-1.02%MU-0.26%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK+2.15%CVX-1.59%0700.HK-0.31%CSCO+1.03%COST-1.30%ORCL+3.55%KO-1.64%UNH-0.08%PG-0.45%BAC+0.32%1816.HK+1.32%3988.HK+0.66%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%0857.HK-0.98%AMAT+2.15%AP2d+2.18%0939.HK+0.81%GE+3.20%1288.HK+0.60%LRCX+1.41%NVS+1.98%0005.HK-5.56%MS+1.91%USDJPY+0.72%EURUSD-0.66%AUDJPY+0.62%EURAUD-0.56%GBPUSD-0.51%USDCHF+0.47%GBPAUD-0.42%GBPTRY+0.41%CADJPY+0.40%AUDCHF+0.39%NZDJPY+0.38%EURNZD-0.35%USDCAD+0.33%NZDUSD-0.33%GBPHKD+0.32%EURCAD-0.32%GBPMXN-0.28%USDTRY+0.27%CHFJPY+0.25%AUDNZD+0.23%AUDCAD+0.22%GBPCAD-0.20%EURCHF-0.20%GBPJPY+0.19%GBPNZD-0.18%USDILS+0.16%NZDCHF+0.15%CADCHF+0.15%EURGBP-0.14%AUDUSD-0.10%EURJPY+0.07%CHFSGD+0.05%GBPCHF-0.05%EURSGD+0.05%AUDSGD+0.05%EURCNH+0.05%USDDKK-0.05%NZDMXN+0.04%USDMXN+0.04%USDCOP-0.04%USDCNH-0.04%USDHKD+0.03%AUDNOK+0.03%USDZAR+0.03%NZDSGD+0.02%USDTHB+0.01%NZDCAD-0.01%SGDJPY+0.01%GBPSGD+0.01%USDSGD0.00%EURPLN0.00%CHFNOK0.00%PLNJPY0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURCZK0.00%EURNOK0.00%EURSEK0.00%EURZAR0.00%GBPZAR0.00%AUDDKK0.00%CHFSEK0.00%USDNOK0.00%EURDKK0.00%XNGUSD+0.44%USOIL-0.22%XPTUSD+0.12%HG1-0.05%GAUUSD-0.05%XAUUSD-0.05%GAGUSD-0.04%XAGUSD-0.03%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.95%ETHUSD+23.96%USDTUSD+0.05%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.79%ZECUSDT+6.40%DOGEUSD+20.65%XMRUSDT+1.68%LINKUSD+25.58%BCHUSDT+4.79%XLMUSD+0.36%UNIUSD-1.14%LTCUSD+17.89%SUIUSD+1.32%HBARUSDT-1.82%TONUSD+41.71%TAOUSDT+1.65%AAVEUSD-1.68%DOTUSDT-1.29%ICPUSDT-1.45%ONDOUSDT+0.94%WLDUSDT+0.37%ARBUSDT-1.45%JUPUSDT+0.30%INJUSDT-1.46%ATOMUSDT-0.82%STXUSDT-1.40%TIAUSDT-2.34%FETUSDT+4.01%PYTHUSDT-3.09%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+0.70%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+0.73%POLUSDT+1.16%AXSUSDT+1.04%EOSUSDT+1.14%FARTCOINUSDT+2.04%DYDXUSDT+2.68%GALAUSDT+1.56%ORDIUSDT+2.76%RONINUSDT+1.89%NOTUSDT+1.92%
EP

Enanta Pharmaceuticals, Inc. (ENTA)

NASDAQ • Healthcare

$12.18
+$0.17 (+1.5%)
Market closed

Last close at October 27, 2026 at 20:00 UTC

Open$11.98
Day Range$11.86 - $12.4
Avg. Volume (3M)275.3K
Market Cap$351.3M
52 Week Range
$10.22$17.15
Next EarningsIn 20 daysNov 16, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$14.3M100%
Gross Profitminus cost of goods$14.3M100%

Fundamentals & Financials

Revenue (TTM)
$65.2M
Net Income (TTM)
-$63.2M
EPS (TTM)
-$2.41
ROA (TTM)
-21.3%
Current Ratio
3.76

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+22.2%Q1 2026-$0.42
+2.2%Q2 2026-$0.45
-31.5%Q3 2026-$0.67
Next

Nov 16

in 20 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Enanta Pharmaceuticals, Inc. (ENTA) reports on November 16, 2026. Wall Street is looking for EPS of -$0.724 on revenue of $14.6 million. For trailing context, revenue declined -21.6% year over year last quarter. ENTA has beaten EPS in 5 of its 8 most recent quarters.

View full earnings history

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on antiviral drug discovery and development. In FY2025, it generated $65.3 million in revenue from a business built around licensed hepatitis C compounds and a pipeline aimed at other viral diseases.

Name
Enanta Pharmaceuticals, Inc.
CEO
Jay R. Luly
Website
www.enanta.com
Industry
Healthcare
Year Founded
1995
Employees
120

Today's Snapshot

AI-generated

The day ended with ENTA 1.5% higher at 12.18, while its sector was flat. Volume was about a quarter more than its usual level. Enanta Pharmaceuticals gave the first patient its treatment in a mid-to-late-stage RSV trial.

Trading Volume

Above 10d avg 243.1K

319.4K

vs S&P 500 Today

Outperforming Market

+0.81%

Updated: October 27, 2026 at 20:16 UTC

Technical Indicators

2 Buy3 Neutral3 Sell
ENTA’s technicals reflect a cautious downgrade driven by its positioning relative to longer-term averages and subdued momentum while trend strength is moderate. The share price sits above short-term moving averages yet below the 50/100/200-day levels, indicating the shorter lift has not translated into a sustained uptrend, and MACD is slightly negative while RSI is neutral. Average true range suggests modest volatility, and on-balance volume is healthy, showing institutional participation that contrasts with the weaker longer-term structure. The pivot level lies below the current price as a short-term support reference. Technical takeaway: overall leaning toward sell due to weakness versus longer-term moving averages.
All signals
  • EMA (5 indicators)$11.79 - $13.08
    Sell
  • RSI (14)51.34
    Neutral
  • Stochastic %K (14, 3, 3)58.42
    Neutral
  • MACD Level (12, 26)-0.25
    Neutral

Peers & Related Assets

AVIRAtea Pharmaceuticals, Inc.
$4.17+0.2%
VYGRVoyager Therapeutics, Inc.
$1.73-1.1%
ASMBAssembly Biosciences, Inc.
NAUTNautilus Biotechnolgy, Inc.
IMRXImmuneering Corporation
PRLDPrelude Therapeutics Incorporated
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.